Biocon, Bristol-Myers sign drug deal


If the US based company exercises the option to licence IN -105, following the successful completion of Phase II trial, the domestic firm will receive a licence fee in addition to potential regulatory and commercial milestone payments and royalties on commercial sales outside India, it added.

Biocon said it will retain the exclusive rights to IN-105 in India.

Bristol-Myers Squibb will assume full responsibility for the development programme, including all development and commercialisation activities outside India, it added.

Commenting on the development, Biocon MD and Chairman Kiran-Mazumdar Shaw said: "This agreement is one huge step closer to realising the dream of bringing oral insulin to market".

Diabetes is a chronic disease that affects about 350 million people worldwide and it is estimated that direct and indirect costs of the disease to overall healthcare system amounts to over USD 650 billion worldwide, Biocon said.

Shares of Biocon were today trading at Rs 304.65 per scrip on BSE, down 0.70 per cent from its previous close.

Please read our terms of use before posting comments
TERMS OF USE: The views expressed in comments published on are those of the comment writer's alone. They do not represent the views or opinions of The Indian Express Group or its staff. Comments are automatically posted live; however, reserves the right to take it down at any time. We also reserve the right not to publish comments that are abusive, obscene, inflammatory, derogatory or defamatory.